Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor–Mutated Non-Small Cell Lung Cancer Patients

BACKGROUND: Erlotinib is presently the first line treatment for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) active mutation. An increasing number of evidences show that the treatment efficacy and toxicities are considerably heterogeneous among individuals. Hence,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Pharmacol
Autors principals: Liao, Dehua, Liu, Zhigang, Zhang, Yongchang, Liu, Ni, Yao, Dunwu, Cao, Lizhi, Chen, Yun, Fu, Yilan, Yang, Nong, Xiang, Daxiong
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7225310/
https://ncbi.nlm.nih.gov/pubmed/32457635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00664
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars